LYEL Lyell Immunopharma
- 2.670
- -0.070-2.55%
Lyell Immunopharma News
Bank of America Securities Keeps Their Buy Rating on Lyell Immunopharma (LYEL)
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‐stage T-cell reprogramming company advancing a diverse pipeline of cell therapies fo
HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $6 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lyell Immunopharma with a Buy and maintains $6 price target.
Lyell Immunopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 136.22% HC Wainwright & Co. → $6 Reiterates Buy → Buy 02/29/2024 136.22% HC Wainwright & Co. $8
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.2%. The iShares Biotechnology ETF (IBB) fell 0.2%. In
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows
Lyell Immunopharma (LYEL) shares were up nearly 4% in recent trading Monday, after Q1 net loss narrowed. The company reported Q1 net loss of $0.24 per diluted share, narrowing from a loss of $0.27 a y
Lyell Immunopharma | 10-Q: Quarterly report
Lyell Immunopharma 1Q Rev $3,000 >LYEL
Lyell Immunopharma 1Q Rev $3,000 >LYEL
Lyell Immunopharma Cash, Cash Equivalents and Marketable Securities of $526.3M as of March 31 >LYEL
Lyell Immunopharma Cash, Cash Equivalents and Marketable Securities of $526.3M as of March 31 >LYEL
Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical--stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March 31, 2024.
Lyell Immunopharma Sees Insider Stock Selling
Viewing insider transactions for Lyell Immunopharma, Inc.'s (NASDAQ:LYEL ) over the last year, we see that insiders were net sellers. This means that a larger number of shares were sold by insiders in
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday's session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billi
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Friday. Shares of Argan, Inc. (NYSE:AGX) rose sharply during Friday's session as the company reported better-than-expected
CERS, GL and ATHE Are Among Pre Market Gainers
GLYC, APLD and AUTL Are Among After Hour Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Market Cap Decline of US$89m May Not Have as Much of an Impact on Institutional Owners After a Year of 1.4% Returns
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‐stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with
Analysis
Price Target
No Data
